drugset / Trial / NCT00693524
Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX
RandomizedParallel-groupOpen-labelTreatment
Summary
Study to evaluate the benefits and any risks of the delayed administration of tacrolimus in a combined regimen of mycophenolate mofetil and monoclonal anti-IL2R antibodies (daclizumab), in comparison with a standard steroid + tacrolimus double drug regimen
Timeline
- Start
- 2002-11
- Primary completion
- 2004-03
- Completion
- 2004-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daclizumab | Monoclonal antibody | — | Intravenous |
| Subject | Mycophenolate Mofetil | Small molecule | — | Oral |
| Comparator | Prednisone | Other / unclassified | — | Oral |
| Subject | Tacrolimus | Small molecule | — | Oral |
Indications
No indication recorded.